Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 19;11(20):6070–6080. doi: 10.7150/jca.44367

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

ZIC2 knockdown sensitized NCI-H1299 cells to cisplatin and paclitaxel treatment. (A) Effects of ZIC2 knockdown on the response to different concentrations of cisplatin in NCI-H1299 cells were evaluated by CCK-8 assays. (B) Effects of ZIC2 knockdown on the response to different concentrations of paclitaxel in NCI-H1299 cells were evaluated by CCK-8 assays. (C) Colony formation assays were conducted to evaluate the effects of ZIC knockdown on cisplatin resistance in NCI-H1299 cells; two concentrations (10 and 20 mM) were selected according to the results of CCK-8 assays. (D) Colony formation assays were conducted to evaluate the effects of ZIC knockdown on paclitaxel resistance in NCI-H1299 cells; two concentrations (0.01 and 1 mM) were selected according to the results of CCK-8 assays. (E) Apoptosis rates of ZIC2-KD and corresponding parental NCI-H1299 cells under different concentrations of cisplatin treatments were determined by FACS. (F) Apoptosis rates of ZIC2-KD and corresponding parental NCI-H1299 cells under different concentrations of paclitaxel treatments were determined by FACS.